The Decipher Prostate Genomic Classifier by Veracyte provides meaningful and independent data to assess the underlying biology and risk of an individual patient’s disease. The test has been validated in over 75 studies of more than 60,000 patients as the most accurate predictor of metastasis, prostate cancer-specific mortality, and overall survival. Decipher Prostate Biopsy helps determine if pati
ents are suitable for active surveillance, if they need monotherapy, or if they may benefit from multi-modality or intensified therapy. Decipher Prostate RP helps determine treatment timing following radical prostatectomy and whether patients undergoing salvage radiotherapy may benefit from the addition of ADT. Developed from a large cohort of post-prostatectomy prostate cancer patients treated at the Mayo Clinic, with long-term follow-up, the whole-transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk. When used in conjunction with clinical information, Decipher provides clarity and confidence in treatment planning. Decipher is covered by Medicare and many private insurance plans throughout the US. It is available to eligible US patients through their physicians. Learn more at www.veracyte.com/decipher
